Researchers used a harmless amoeba to safeguard children from dangerous colitis (C. difficile) infections, revealed a study. The Hartwell Foundation which supports early-stage, cutting-edge biomedical ...

The research team comprised of Shin Kurihara, Associate Professor of Department of Science and Technology on Food Safety, Faculty of Biology-Oriented Science and Technology, Kindai University ...

Four patients with severe disease were cured after receiving the new broad-spectrum antibiotic tigecycline. When patients with Clostridium difficile colitis do not respond to usual treatment with ...

An inflammation of the colon associated with C. difficile — C. difficile colitis — has increased nearly 50 percent from 2001-2005 to 2006-2010, according to a study in the Journal of the American ...

Please provide your email address to receive an email when new articles are posted on . Aiming to assess durability of FMT in patients with moderate to severe IBD, Loftus and colleagues conducted a ...

PHILADEPHIA — Both initial and sustained responses to fecal microbiota transplant (FMT) for the treatment of refractory C difficile infection remain high out to 18 months' follow-up, provided patients ...

New research from the University of Virginia School of Medicine's William A. Petri Jr., MD, PhD, (left) and David Tyus suggests that doctors may be able to save patients from dangerous C. difficile ...

This page lists all known medications that could potentially lead to 'Clostridium difficile colitis' as a side effect. It's important to note that mild side effects are quite common with medications.

The portion of our nervous systems responsible for the 'fight or flight' response can shape the severity of potentially deadly C. difficile infections, according to new research. The portion of our ...

SALT LAKE CITY, May 25, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across ...

Company shifts focus to phase 3 VE303 trial in recurrent C. difficile infection Vedanta Biosciences has announced that VE202 failed to meet the primary endpoint in its phase 2 COLLECTiVE202 study for ...